Filing Flows › Moderna (MRNA) › Q2 2026 › vs Q1 2026
Moderna (MRNA) Q2 2026 vs Q1 2026 (quarter over quarter)
Moderna's revenue fell $244M (-63%) from $389M in Q1 2026 to $145M in Q2 2026.
Moderna, Q2 2026: revenue $145M (+2% year over year), operating margin -562.1%, net loss $782M, operating cash flow −$526M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $145M | $389M | −$244M | -63% |
| Other income, net | $48.0M | $54.0M | −$6.0M | -11% |
| Net loss | $782M | $1.3B | −$561M | -42% |
| Costs & expenses | $975M | $1.8B | −$811M | -45% |
| Operating costs | $960M | $1.8B | −$817M | -46% |
| Income tax | $15.0M | $9.0M | $6.0M | +67% |
| Cost of revenue | $93.0M | $955M | −$862M | -90% |
| Research & development | $651M | $649M | $2.0M | +0.3% |
| General & admin | $216M | $173M | $43.0M | +25% |
| Operating cash sources | $782M | $1.3B | −$561M | -42% |
| Depreciation & amortization | $56.0M | $56.0M | $0 | 0% |
| Share-based compensation | $120M | $104M | $16.0M | +15% |
| Working capital & other | $80.0M | $553M | −$473M | -86% |
| Cash used in operations | $526M | $630M | −$104M | -17% |
| Net loss absorbed | $782M | $1.3B | −$561M | -42% |
Questions
How much did Moderna's revenue grow quarter over quarter in Q2 2026?
Moderna's revenue fell $244M (-63%) from $389M in Q1 2026 to $145M in Q2 2026.